Skip to main content

Table 4 Summary of clinical outcomes in patients who are human immunodeficiency virus positive and patients who are not human immunodeficiency virus positive referred for bariatric surgery

From: Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series

 

Baseline

BMI

%TWL

postop after 2 years

%EWL

postop after 2 years

HbA1c

Complete remission of T2DM1

Preop

Postop after 1 year

HIV case 1 (AGB)

46.6

24.4%

52.6%

41

33

No

HIV case 2 (SG)

50.7

25.2%

49.8%

35

32

Yes

HIV case 3 (SG)

47.8

14.1%

29.5%

128

90

No

AGB-non HIV (n = 61)

43.4 ± 6.2

14% ± 8%

34% ± 22%

60.6 ± 18.1

58.2 ± 13.5

5%

SG-non HIV (n = 56)

49.6 ± 10.7

22% ± 9%

42% ± 20%

59.5 ± 18.5

54.4 ± 18.1

27%

  1. AGB adjustable gastric band, BMI body mass index, EWL excessive weight loss, HbA1c glycated hemoglobin, HIV human immunodeficiency virus, SG sleeve gastrectomy, T2DM type 2 diabetes mellitus, TWL total weight loss. 1 according to American Diabetes Association criteria [8]. Data in non-HIV group were described as mean ± standard deviation